SCHEMBL34464802

SCHEMBL34464802

CC1CCN(C(=O)c2ccc(Nc3nccc(-c4ccc(C(=O)NO)cc4)n3)cc2F)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 11/20 0.53
▸ HDAC1 Q13547 6/20 0.53
▸ JAK3 P52333 5/20 0.53
▸ HDAC8 Q9BY41 2/20 0.53
▸ JAK1 P23458 2/20 0.53
▸ HDAC3 O15379 1/20 0.53
▸ NCOR1 O75376 1/20 0.53
▸ TYK2 P29597 1/20 0.53
▸ HDAC2 Q92769 1/20 0.53
▸ HDAC6 Q9UBN7 1/20 0.53
▸ CAMK2D Q13557 2/20 0.52
▸ CDC7 O00311 1/20 0.46
▸ CDK19 Q9BWU1 1/20 0.46
▸ CDK1 P06493 1/20 0.45
▸ CDK2 P24941 1/20 0.45
▸ CDK4 P11802 1/20 0.43
▸ CDKL1 Q00532 1/20 0.43
▸ KCNH2 Q12809 1/20 0.43
▸ IKBKB O14920 1/20 0.43
▸ CHUK O15111 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL34464820 0.90 JAK2 (0.54) JAK2HDAC1JAK3HDAC8JAK1
SCHEMBL34464746 0.88 JAK2 (0.67) JAK2HDAC1JAK3HDAC8JAK1
SCHEMBL34464800 0.87 JAK2 (0.54) JAK2HDAC1JAK3HDAC8JAK1
Formic Acid SCHEMBL34464810 0.87 JAK2 (0.51) JAK2HDAC1JAK3HDAC8JAK1
SCHEMBL34464812 0.84 JAK2 (0.46) JAK2HDAC1JAK3HDAC8JAK1
SCHEMBL34464773 0.84 JAK2 (0.52) JAK2HDAC1JAK3HDAC8JAK1
SCHEMBL34464867 0.81 CAMK2D (0.53) JAK2JAK3CAMK2DCDK1CDK2
SCHEMBL34464796 0.79 SYK (0.50) JAK2JAK3CAMK2DCDK1CDK2
SCHEMBL34464794 0.79 JAK2 (0.56) JAK2HDAC1JAK3HDAC8JAK1
SCHEMBL34464745 0.79 JAK2 (0.56) JAK2HDAC1JAK3HDAC8JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109690-A1 HDAC6 INHIBITORS AND METHOD OF THEIR USE BAERENKRAFT THERAPEUTICS LLC (US) 2026-04-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260109690-A1 HDAC6 INHIBITORS AND METHOD OF THEIR USE HDAC6, HDAC3, HDAC1 JAK2 2639/4885HDAC1 3/4885JAK3 3362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback